GEMATOLOGIK XAVFLI O‘SMALARDA NEVROLOGIK BUZILISHLAR: TAQQOSLAMA TAHLIL
##article.subject##:
nevrologik buzilishlar, gematologik xavfli o‘smalar, o‘tkir limfoblast leykoz, o‘tkir miyeloid leykoz, limfoma, kognitiv buzilishlar##article.abstract##
Tadqiqot maqsadi: turli xil gematologik xavfli o‘smalarga chalingan bemorlarda nevrologik buzilishlarning uchrashish chastotasi va xususiyatlarini o‘rganish. Materiallar va usullar: Gematologik xavfli o‘smalarga ega bo‘lgan 111 nafar bemorda prospektiv tadqiqot o‘tkazildi: o‘tkir limfoblast leykoz (O‘LL, n=64), o‘tkir miyeloid leykoz (O‘ML, n=28) va limfoma (n=19). Tadqiqot davomida kognitiv buzilishlar, diqqat yetishmovchiligi, bosh og‘rig‘i, periferik neyropatiya, harakat koordinatsiyasi buzilishlari hamda vegetativ distoniya baholandi. Natijalar: Kognitiv buzilishlar O‘LL bilan kasallangan bemorlarda (63,5±6,2%) O‘ML (57,1±8,6%) va limfoma (38,5±14,6%) bilan taqqoslaganda statistik jihatdan ishonchli ravishda ko‘proq uchradi (p<0,001). Boshqa nevrologik namoyonlar guruhlar o‘rtasida statistik ahamiyatli farq ko‘rsatmadi (p>0,05). Xulosa: O‘LL bilan kasallangan bemorlarda kognitiv buzilishlar rivojlanish xavfi yuqori bo‘lib, bu holat davolash va reabilitatsiya tadbirlarini rejalashtirishda alohida e’tibor talab qiladi.
Библиографические ссылки
Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol. 2010;30(3):273-286. doi:10.1055/s-0030-1255217
Taillibert S, Chamberlain MC. Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep. 2011;11(1):48-54. doi:10.1007/s11910-010-0147-9
Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16(9):535-548. doi:10.1038/s41571-019-0194-4
Pruitt AA. Neurologic complications of hematopoietic cell transplantation. Neurol Clin. 2010;28(4):1097-1112. doi:10.1016/j.ncl.2010.03.021
Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49(1-2):92-104. doi:10.1159/000069773
Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose Ara-C. Neurology. 1985;35(9):1475-1479. doi:10.1212/wnl.35.10.1475
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14 Suppl 4:iv45-iv54. doi:10.1093/neuonc/nos203
Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):58-66. doi:10.1016/j.semradonc.2009.09.005
Siegal D, Keller A, Xu W, et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13(10):1369-1379. doi:10.1016/j.bbmt.2007.07.013
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972
Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123-138. doi:10.3322/caac.21258
Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407-4415. doi:10.1200/JCO.2012.48.2315
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. doi:10.1016/j.pain.2014.09.020
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399
